All Insights Report Novel Drug Approvals by the U.S. Food and Drug Administration in Rare Diseases: Findings From 2020–2023

    Novel Drug Approvals by the U.S. Food and Drug Administration in Rare Diseases: Findings From 2020–2023

    RWE, HEOR & Evidence Synthesis

    Novel Drug Approvals by the U.S. Food and Drug Administration in Rare Diseases: Findings From 2020–2023

    This study examines trends in rare disease drug development through a systematic review of FDA CDER-approved novel drugs (NDAs) between 2020 and 2023, aiming to address clinical and humanistic burdens by analyzing indication types, approval categories, regulatory pathways, and trial endpoints, including patient-reported outcomes (PROs).

    Download Report
    Novel Drug Approvals by the U.S. Food and Drug Administration in Rare Diseases: Findings From 2020–2023

    Rare diseases, affecting fewer than 200,000 individuals in the U.S., present significant challenges due to the lack of effective treatments, leading to substantial clinical and humanistic burdens. Novel therapies offer the potential to improve patient outcomes and quality of life. The FDA Center for Drug Evaluation and Research (CDER) has been instrumental in fostering pharmaceutical innovations, with a notable increase in novel drug approvals (NDAs) for rare diseases. This study systematically reviews NDAs granted by the CDER for rare diseases between 2020 and 2023 to understand trends in rare disease drug development. All novel drugs approved during this period were identified using the FDA drug database. Data was collected from drug labels, approval letters, and FDA submission documents, focusing on the number of NDAs, indication types, approval categories, regulatory pathways, and trial endpoints, including patient-reported outcomes (PROs).

    This report is a poster presentation of Axtria from ISPOR 2024.

    Contact us at connect@axtria.com with any questions.

    Complete the brief form to download the white paper

    Recommended insights

    Findings From 2020–2023

    Report

    The Inflation Reduction Act and Its Implications on Real-World Evidence

    Findings From 2020–2023

    Report

    The Use of Natural Language Processing in Literature Reviews

    Findings From 2020–2023

    Article

    Navigating the Pharma Commercial Models for Rare Diseases